期刊
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
卷 18, 期 6, 页码 1393-+出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2020.01.033
关键词
CTLA-4; Immune Checkpoint Inhibitors; PD1; Enterocolitis; Immune-Related Adverse Effect; Colitis; Enteritis; Immunotherapy
资金
- Fondation pour la Recherche Medicale doctoral grant [FDM 20170839109]
Immune checkpoint inhibitors (ICIs) have improved the treatment of several cancers. These drugs increase T-cell activity and the antitumor immune response but also have immune-related adverse effects that can affect the gastrointestinal (GI) tract. These adverse effects have been observed in 7% to 30% of patients treated with ICIs. As the number of diseases treated with ICIs increases, gastroenterologists will see more patients with ICI-induced GI adverse events. We performed a systematic review of the incidence, risk factors, clinical manifestations, and management of the adverse effects of ICIs on the GI tract. Treatment with anti-cytotoxic T-lymphocyte-associated antigen-4 often causes severe enterocolitis, whereas treatment with inhibitors of programmed cell death 1 have less frequent and more diverse adverse effects. Management of patients with GI adverse effects of ICIs should involve first ruling out other disorders, followed by assessment of severity, treatment with corticosteroids, and rapid introduction of infliximab therapy for nonresponders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据